Published in PLoS One on February 03, 2014
Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions. PLoS One (2014) 0.88
Exploiting Literature-derived Knowledge and Semantics to Identify Potential Prostate Cancer Drugs. Cancer Inform (2014) 0.82
iRSpot-GAEnsC: identifing recombination spots via ensemble classifier and extending the concept of Chou's PseAAC to formulate DNA samples. Mol Genet Genomics (2015) 0.82
A computational method for the identification of candidate drugs for non-small cell lung cancer. PLoS One (2017) 0.75
Global cancer statistics. CA Cancer J Clin (2011) 185.92
KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res (2000) 117.00
DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res (2006) 15.19
Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov (2004) 7.57
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Network-based prediction of protein function. Mol Syst Biol (2007) 6.13
Discovery and preclinical validation of drug indications using compendia of public gene expression data. Sci Transl Med (2011) 5.77
Computational repositioning of the anticonvulsant topiramate for inflammatory bowel disease. Sci Transl Med (2011) 5.30
STITCH: interaction networks of chemicals and proteins. Nucleic Acids Res (2007) 4.88
Discovery of drug mode of action and drug repositioning from transcriptional responses. Proc Natl Acad Sci U S A (2010) 4.35
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol (2008) 4.29
Exploiting indirect neighbours and topological weight to predict protein function from protein-protein interactions. Bioinformatics (2006) 3.94
The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med (2004) 3.50
Phase II study of SMILE chemotherapy for newly diagnosed stage IV, relapsed, or refractory extranodal natural killer (NK)/T-cell lymphoma, nasal type: the NK-Cell Tumor Study Group study. J Clin Oncol (2011) 3.10
STITCH 2: an interaction network database for small molecules and proteins. Nucleic Acids Res (2009) 3.06
Drug discovery. Repurposing with a difference. Science (2009) 2.97
Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy. N Engl J Med (1990) 2.73
Prediction of drug-target interactions and drug repositioning via network-based inference. PLoS Comput Biol (2012) 2.63
The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans (2010) 2.48
Prediction of protein function using protein-protein interaction data. J Comput Biol (2003) 2.15
Temozolomide as salvage treatment in primary brain lymphomas. Br J Cancer (2007) 1.81
Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol (2009) 1.71
Metaplastic breast carcinomas are negative for Her-2 but frequently express EGFR (Her-1): potential relevance to adjuvant treatment with EGFR tyrosine kinase inhibitors? J Clin Pathol (2005) 1.55
Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma. J Clin Oncol (1999) 1.54
Lomustine (CCNU) for the treatment of resistant lymphoma in dogs. J Vet Intern Med (1999) 1.54
What do medicinal chemists actually make? A 50-year retrospective. J Med Chem (2011) 1.47
Predicting Anatomical Therapeutic Chemical (ATC) classification of drugs by integrating chemical-chemical interactions and similarities. PLoS One (2012) 1.43
Predicting functions of proteins in mouse based on weighted protein-protein interaction network and protein hybrid properties. PLoS One (2011) 1.32
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol (1989) 1.28
Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. J Clin Oncol (2004) 1.28
Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat (1999) 1.27
Preclinical validation of electrochemotherapy as an effective treatment for brain tumors. Cancer Res (2011) 1.27
Use of fuzzy clustering technique and matrices to classify amino acids and its impact to Chou's pseudo amino acid composition. J Theor Biol (2008) 1.26
Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist (2006) 1.17
Long-term effectiveness of adjuvant goserelin in premenopausal women with early breast cancer. J Natl Cancer Inst (2009) 1.13
A multicentre dose-escalating study of cabazitaxel (XRP6258) in combination with capecitabine in patients with metastatic breast cancer progressing after anthracycline and taxane treatment: a phase I/II study. Eur J Cancer (2011) 1.13
Classification and analysis of regulatory pathways using graph property, biochemical and physicochemical property, and functional property. PLoS One (2011) 1.11
The low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium. Eur J Cancer (2011) 1.10
Antitumor effect of cisplatin against murine ascites Dalton's lymphoma. Indian J Exp Biol (1994) 1.08
A new multidrug reinduction protocol with topotecan, vinorelbine, thiotepa, dexamethasone, and gemcitabine for relapsed or refractory acute leukemia. Leukemia (2003) 1.07
Prediction of protein functions based on function-function correlation relations. Comput Biol Med (2010) 1.07
Efficacy and safety of gemcitabine, carboplatin, dexamethasone, and rituximab in patients with relapsed/refractory lymphoma: a prospective multi-center phase II study by the Puget Sound Oncology Consortium. Leuk Lymphoma (2010) 1.02
Mitotane for adrenocortical carcinoma treatment. Curr Opin Investig Drugs (2005) 1.02
Predicting biological functions of compounds based on chemical-chemical interactions. PLoS One (2011) 0.99
CCNU in the treatment of canine epitheliotropic lymphoma. J Vet Intern Med (2006) 0.99
CCNU (lomustine) toxicity in dogs: a retrospective study (2002-07). Aust Vet J (2011) 0.98
p53-independent apoptosis induced by genistein in lung cancer cells. Nutr Cancer (1999) 0.95
A multi-center phase II study of BMS-247550 (Ixabepilone) by two schedules in patients with metastatic gastric adenocarcinoma previously treated with a taxane. Invest New Drugs (2006) 0.94
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss. Mol Cancer Ther (2010) 0.93
Recent progress in predicting protein sub-subcellular locations. Expert Rev Proteomics (2011) 0.91
Prediction of human genes' regulatory functions based on proteinprotein interaction network. Protein Pept Lett (2012) 0.89
Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement. J Clin Endocrinol Metab (2012) 0.89
Predicting protein phenotypes based on protein-protein interaction network. PLoS One (2011) 0.87
Oral vinorelbine in metastatic breast cancer: a review of current clinical trial results. Cancer Treat Rev (2011) 0.87
Predicting chemical toxicity effects based on chemical-chemical interactions. PLoS One (2013) 0.87
An exploratory study of sunitinib plus paclitaxel as first-line treatment for patients with advanced breast cancer. Ann Oncol (2009) 0.87
Localized conjunctival mucosa-associated lymphoid tissue (MALT) lymphoma is amenable to local chemotherapy. Int Ophthalmol (2007) 0.87
A clinical trial of intravenous bleomycin in the treatment of brain tumors. Int J Clin Pharmacol Biopharm (1975) 0.86
Predicting metabolic pathways of small molecules and enzymes based on interaction information of chemicals and proteins. PLoS One (2012) 0.85
Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother (2005) 0.85
Zoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment? Breast Cancer Res (2012) 0.83
Combination chemotherapy with L-asparaginase, lomustine, and prednisone for relapsed or refractory canine lymphoma. J Vet Intern Med (2007) 0.83
The synergistic anti-neoplastic activity of combinations of mitomycins with either 6-thioguanine or 5-fluorouracil. Cancer Res (1965) 0.83
Xeloda in the treatment of metastatic breast cancer. Oncology (1999) 0.83
Metastatic adrenal cortical carcinoma. Prolonged regression with mitotane therapy. JAMA (1981) 0.82
Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol (2003) 0.82
Topical application of valrubicin has a beneficial effect on developing skin tumors. Carcinogenesis (2010) 0.82
Vinorelbine as first-line chemotherapy for advanced breast cancer in women 60 years of age or older. Ann Oncol (1999) 0.82
Prevention of lung cancer progression by bexarotene in mouse models. Oncogene (2006) 0.81
Reduced intensity conditioning with thiotepa, fludarabine, and melphalan is effective in advanced multiple myeloma. Leuk Lymphoma (2007) 0.81
ECOH: an enzyme commission number predictor using mutual information and a support vector machine. Bioinformatics (2012) 0.81
Combination of CCNU and DTIC chemotherapy for treatment of resistant lymphoma in dogs. J Vet Intern Med (2008) 0.81
Methylazoxyprocarbazine, the active metabolite responsible for the anticancer activity of procarbazine against L1210 leukemia. Cancer Res (1989) 0.80
Phase II study of bi-weekly irinotecan for patients with previously treated HER2-negative metastatic breast cancer: KMBOG0610B. Breast Cancer (2011) 0.79
Irinotecan combined with docetaxel in pre-treated metastatic breast cancer patients: a phase II study. Cancer Chemother Pharmacol (2005) 0.79
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum. Lung Cancer (2011) 0.79
Prediction of P53 mutants (multiple sites) transcriptional activity based on structural (2D&3D) properties. PLoS One (2013) 0.79
Phase II trial of oral etoposide in recurrent or refractory endometrial adenocarcinoma: a southwest oncology group study. Gynecol Oncol (1999) 0.78
Fludarabine and epirubicin in the treatment of chronic lymphocytic leukaemia: a German multicenter phase II study. Ann Oncol (1999) 0.77
The retinoid X receptor agonist bexarotene (Targretin) synergistically enhances the growth inhibitory activity of cytotoxic drugs in non-small cell lung cancer cells. Lung Cancer (2005) 0.77
Prospective trial of cisplatin, adriamycin, and dacarbazine in metastatic mixed mesodermal sarcomas of the uterus and ovary. Am J Clin Oncol (1991) 0.76
A phase II trial of ixabepilone in Asian patients with advanced gastric cancer previously treated with fluoropyrimidine-based chemotherapy. Cancer Chemother Pharmacol (2012) 0.76
Etoposide (VP-16), ifosfamide/mesna, and cisplatin chemotherapy for advanced and recurrent carcinoma of the cervix. Gynecol Oncol (1991) 0.76
The antiandrogen flutamide inhibits growth of mcf-7 human breast-cancer cell-line. Int J Oncol (1993) 0.76
Phase II study of weekly mitoxantrone, 5-fluorouracil, and leucovorin in metastatic breast cancer. Breast Cancer Res Treat (1994) 0.76
[Etoposide (VP-16) in gynecologic malignancy]. Gan To Kagaku Ryoho (1996) 0.76
Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C. J Antibiot (Tokyo) (1983) 0.76
DNA damage by anthracycline drugs in human leukemia cells. Cancer Lett (1981) 0.76
Influence of fluoxymesterone on in vitro erythropoiesis affected by leukemic cells. Exp Hematol (1984) 0.76
[Successful treatment of advanced esophageal cancer with lymph node metastases by docetaxel, cisplatin and 5-FU followed by salvage lymphadenectomy--a case report]. Gan To Kagaku Ryoho (2010) 0.76
Childhood malignant tumors. Concurrent chemotherapy with dactinomycin and vincristine sulfate. JAMA (1966) 0.76
Finding candidate drugs for hepatitis C based on chemical-chemical and chemical-protein interactions. PLoS One (2014) 0.88
Analysis of tumor suppressor genes based on gene ontology and the KEGG pathway. PLoS One (2014) 0.78
A Shortest-Path-Based Method for the Analysis and Prediction of Fruit-Related Genes in Arabidopsis thaliana. PLoS One (2016) 0.75